^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KAT6A-CREBBP fusion + FLT3-TKD mutation

    i
    Other names: KAT6A, Lysine Acetyltransferase 6A, MOZ, Monocytic Leukemia Zinc Finger Protein, ZC2HC6A, RUNXBP2, ZNF220, MYST3, MYST Histone Acetyltransferase (Monocytic Leukemia) 3, Runt-Related Transcription Factor Binding Protein 2, MOZ, YBF2/SAS3, SAS2 And TIP60 Protein 3, Histone Acetyltransferase KAT6A, K(Lysine) Acetyltransferase 6A, Zinc Finger Protein 220, MYST-3, Runt-Related Transcription Factor-Binding Protein 2, Histone Acetyltransferase MYST3, ARTHS, MRD32, CREBBP, CBP, KAT3A, RSTS, RTS, CREB binding protein , FLT3, Fms Related Tyrosine Kinase 3, Receptor-Type Tyrosine-Protein Kinase FLT3, Stem Cell Tyrosine Kinase 1, Fms-Like Tyrosine Kinase 3, CD135, FLK-2, STK1, Growth Factor Receptor Tyrosine Kinase Type III, Fetal Liver Kinase 2
    Entrez ID:
    2322; 1387; 7994
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over1year
    De novo monocytic-M5b AML with t(8;16) (p11.2; p13.3) KAT6A/CREBBP fusion and FLT3-TKD mutation complicated by chemotherapy-induced Takotsubo cardiomyopathy. (PubMed, BMJ Case Rep)
    Our patient died in 6 months from the date of diagnosis. Although a rare occurrence, it has been discussed in literature to identify t(8;16) as a separate subtype of AML due to unique characteristics.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • CREBBP (CREB binding protein) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • KAT6A (Lysine Acetyltransferase 6A)
    |
    FLT3-TKD mutation • PTPRC expression • KAT6A-CREBBP fusion + FLT3-TKD mutation
    2years
    AML-336 De Novo M5b AML With t(8;16) (p11.2; p13.3) KAT6A/CREBBP Fusion and FLT3-TKD Mutation: Analysis of Mitelman Database. (PubMed, Clin Lymphoma Myeloma Leuk)
    Mitelman database analysis reveals that a vast majority of cases with t(8;16) are either M4 or M5 AML. Careful consideration of treatment options would be recommended based on age as chromosomal abnormalities play a major role in prognosis, especially with t(8;16).
    Journal • IO biomarker
    |
    FLT3 (Fms-related tyrosine kinase 3) • CD38 (CD38 Molecule) • CREBBP (CREB binding protein) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • TFRC • KAT6A (Lysine Acetyltransferase 6A)
    |
    FLT3-TKD mutation • KAT6A-CREBBP fusion + FLT3-TKD mutation
    |
    cytarabine • Rydapt (midostaurin) • daunorubicin